FMP
Eiger BioPharmaceuticals, Inc.
EIGR
NASDAQ
Inactive Equity
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
1.73 USD
-0.175 (-10.14%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. David Apelian M.B.A., M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.eigerbio.comexchange
NASDAQ
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clini...
CIK
0001305253
ISIN
US28249U2042
CUSIP
28249U105
Address
2155 Park Boulevard
Phone
650 272 6138
Country
US
Employee
56
IPO Date
Jan 30, 2014
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
EIGR Financial Summary
CIK
0001305253
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
28249U105
ISIN
US28249U2042
Country
US
Price
1.73
Beta
1.84
Volume Avg.
113.73k
Market Cap
2.55M
Shares
-
52-Week
1.1-43.35
DCF
-0.36
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.03
P/B
-
Website
https://www.eigerbio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EIGR News
It looks like there's no news available.
